Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment
-
Published:2024-07
Issue:
Volume:42
Page:100923
-
ISSN:2666-7762
-
Container-title:The Lancet Regional Health - Europe
-
language:en
-
Short-container-title:The Lancet Regional Health - Europe
Author:
Boertien Tessel M.ORCID,
Drent Madeleine L.,
Booij Jan,
Majoie Charles B.L.M.,
Stokkel Marcel P.M.,
Hoogmoed Jantien,
Pereira Alberto M.,
Biermasz Nienke R.,
Simsek Suat,
Veldman Ronald Groote,
Weterings Annick J.,
Vink Juan M.,
Tanck Michael W.T.,
Fliers Eric,
Bisschop Peter H.